Prognostic Role of Specific <i>KRAS</i> Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer.

ABSTRACT: Background/Objectives: Although the overall survival prognosis of patients in advanced stages of pancreatic ductal adenocarcinoma (PDAC) is poor, typically ranging from days to months from diagnosis, there are rare cases of patients remaining in therapy for longer periods of time. Early estimations of survival prognosis would allow rational decisions on complex therapy interventions, including radical surgery and robust systemic therapy regimens. Understandably, there is great interest in finding prognostic markers that can be used for patient stratification. We determined the role of various KRAS mutations in the prognosis of PDAC patients using biopsy samples and circulating tumor DNA. Methods: A total of 118 patients with PDAC, clinically confirmed by endoscopic ult

SUBMITTER: Halkova T 

PROVIDER: S-EPMC11507146 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature